All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Mosunetuzumab for the treatment of high-risk, heavily pretreated R/R follicular lymphoma
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
In a subgroup analysis of the phase II GO29781 trial of mosunetuzumab, which group of patients experienced the highest complete response rate?
A
B
C
D
|
A subgroup analysis from the pivotal phase II GO29781 (NCT02500407) study of mosunetuzumab was presented at the EHA 2024 Congress by Sarit Assouline.1 This analysis primarily focused on outcomes among patients with high-risk, heavily pretreated R/R FL with ≥3 years of follow-up. Subgroups included patients with a history of POD24, patients receiving mosunetuzumab in the 3L vs 4L or later, and patients aged ≥65 years.1
|
| Key learnings: |
|
In the subgroup analysis, ORR rates were 78%, 74%, and 81% in the overall, non-POD24, and POD24 populations, respectively. |
|
Rates of CR did not differ significantly across the subgroups, with the highest CR rate (68.6%) observed in patients treated with mosunetuzumab in the 3L (compared with 54.5% in patients treated in the 4L or later). |
|
The 3-year PFS rate did not differ significantly between groups and was 43%, 44%, and 42% for the overall, non-POD24, and POD24 populations, respectively. |
|
The 3-year OS rates were also similar across subgroups (83%, 81%, and 84% for the overall, non-POD24, and POD24 populations, respectively). |
|
The safety profile for each subgroup, including in older patients aged ≥65 years, was largely consistent with that for the overall population. |
|
Overall, fixed-duration mosunetuzumab resulted in consistently favorable outcomes across subgroups of patients with high-risk R/R FL, including those with POD24, and in older patients. Efficacy outcomes may be improved with mosunetuzumab use in earlier rather than later lines of treatment. |
Abbreviations: 3L, third-line; 4L, fourth-line; EHA, European Hematology Association; CR, complete response; FL, follicular lymphoma; OS, overall survival; PFS, progression-free survival; POD24, progression of disease within 24 months from the start of first-line therapy; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
